Stephen huang
Executive Director, Clinical Biomarkers & CDx Avenzo Therapeutics
Stephen Huang is Executive Director, Clinical Biomarkers and Companion Diagnostics at Avenzo Therapeutics, a role held since March 2024. Previously, Stephen held executive roles in biomarker and companion diagnostics at Artiva Biotherapeutics and Turning Point Therapeutics, and was Director, Companion Diagnostics Strategy Lead at AbbVie. Earlier experience includes eight years at Pfizer, plus roles at Spectrum Pharmaceuticals, Exelixis and Quest Diagnostics.
Seminars
Friday 19th March 2027
Panel Discussion: Choosing the Right Diagnostic Partner for the Right Study to Deliver Regulatory-Grade Liquid Biopsy Data
3:00 pm
- Matching assay type, sensitivity and turnaround to the study question, from patient selection and enrichment to response monitoring and MRD
- Evaluating vendors on analytical validation, quality systems and regulatory track record, so data stands up to agency scrutiny
- Structuring the sponsor and vendor relationship early, from contracting and sample logistics to bridging plans if the assay changes mid-program
